GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Price-to-Owner-Earnings

Biosyent (Biosyent) Price-to-Owner-Earnings

: 20.86 (As of Today)
View and export this data going back to . Start your Free Trial

As of today (2024-04-19), Biosyent's share price is $6.2565. Biosyent's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.30. It's Price-to-Owner-Earnings for today is 20.86.


The historical rank and industry rank for Biosyent's Price-to-Owner-Earnings or its related term are showing as below:

BIOYF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.85   Med: 20.75   Max: 61.3
Current: 20.6

During the past 13 years, the highest Price-to-Owner-Earnings of Biosyent was 61.30. The lowest was 11.85. And the median was 20.75.


BIOYF's Price-to-Owner-Earnings is ranked better than
61.05% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.51 vs BIOYF: 20.60

As of today (2024-04-19), Biosyent's share price is $6.2565. Biosyent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.39. Therefore, Biosyent's PE Ratio for today is 15.88.

As of today (2024-04-19), Biosyent's share price is $6.2565. Biosyent's EPS without NRI for the trailing twelve months (TTM) ended in was $0.40. Therefore, Biosyent's PE Ratio without NRI for today is 15.80.

During the past 13 years, Biosyent's highest PE Ratio without NRI was 70.83. The lowest was 9.27. And the median was 23.76.


Biosyent Price-to-Owner-Earnings Historical Data

The historical data trend for Biosyent's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.81 15.99 25.23 19.28 21.76

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.28 26.43 17.77 14.75 21.76

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Biosyent's Price-to-Owner-Earnings falls into.



Biosyent Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Biosyent's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.2565/0.30
=20.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (OTCPK:BIOYF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Biosyent Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Biosyent's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent Declares Second Quarter 2023 Dividend

By GlobeNewswire GlobeNewswire 05-25-2023